FDA orders warning labels on GLP‑1 weight‑loss drugs for rare eye condition
The US Food and Drug Administration has required manufacturers of GLP‑1 drugs such as Ozempic and Wegovy to add warnings about a rare eye condition that can…
The US Food and Drug Administration has required manufacturers of GLP‑1 drugs such as Ozempic and Wegovy to add warnings about a rare eye condition that can lead to blindness, the BBC reported. The agency said the condition, known as non‑arteritic anterior ischemic optic neuropathy (NAION), has been linked to the use of these weight‑loss medications. Labels will now need to inform patients of the potential risk, prompting doctors to discuss the issue when prescribing the drugs. The move aims to ensure users are aware of the possible side effect and can monitor any visual changes promptly.
Why it matters
The warning helps patients and clinicians recognize a serious, though rare, risk associated with popular weight‑loss drugs.
Key details
- Location
- United States · Americas
- Reported by
- BBC News
- First reported
- Key names
- Makers of GLP-, US Food, Drug Administration, Ozempic
- Section
- Health
Sources
This is an independent summary. Read the full, original reporting from the publisher:
Read the full story at BBC NewsSpotted an error? Request a correction · How this summary was produced
Related Stories
FDA orders warning labels for GLP‑1 weight‑loss drugs over rare eye disease
The U.S. Food and Drug Administration has issued a new warning about a rare eye condition that can cause sudden, permanent blindness in patients…
FDA drops black‑box warnings from three menopause patches without advisory panel
The US Food and Drug Administration announced on Friday that black‑box warnings will be removed from three estrogen patches used to treat menopause…
Ozempic and Wegovy linked to rare risk of sudden vision loss
Popular diabetes and weight loss drugs such as Ozempic and Wegovy have been linked to a slightly increased risk of a rare condition that can cause…
Popular weight loss drugs linked to a surprising fingernail problem
Popular GLP-1 weight loss drugs, such as Ozempic and Wegovy, have been linked to unexpectedly high rates of nail detachment, hair loss, and scalp…
Study finds people in England's poorest areas face double the risk of early death
The Guardian reported that people living in the most deprived areas of England are more than twice as likely to die prematurely than those in…
US measles deaths prompt calls for stronger vaccination policy
The United States reported three measles-related deaths last week, including a seven-month-old infant in New York and a postpartum woman in…
Experts warn weight‑loss drug rush could jeopardise insulin supply
The Guardian reported that a surge in GLP‑1 weight‑loss drugs may threaten the availability of insulin, a core treatment for diabetes.
Police probe illness of nearly 30 runners at Santa Barbara half marathon
Police in southern California opened an investigation after almost 30 participants in the Santa Barbara Half marathon sought medical treatment for…